Table 1 |
||||
|
Clinical features of patients with anti-TIF1β autoantibodies. |
||||
|
1 |
2 |
3 |
4 |
|
|
|
||||
|
Diagnosis |
DM |
UCTD |
DM |
DM |
|
Symmetrical muscle weakness |
P |
N |
P |
Y |
|
Muscle biopsy |
Y |
ND |
ND |
NA |
|
Elevated muscle enzyme |
Y |
Y |
Y |
Y |
|
EMG |
myopathic pattern |
myopathic pattern |
myopathic pattern |
NA |
|
Dermatologic features |
Y (G) |
N |
P (S) |
Y (G, H, S) |
|
Malignancy |
N |
Y |
N |
N |
|
Interstitial lung disease |
N |
N |
N |
N |
|
Dysphagia |
Y |
N |
N |
N |
|
Raynaud's phenomenon |
N |
N |
N |
N |
|
Arthritis |
N |
Y |
N |
N |
|
CPK (U/L) initial /after Tx (lowest) |
654 167 |
341 239 |
314 |
2414 |
|
Initial Tx |
none |
PSL 10 mg |
PSL 40 mg |
PSL 50 mg |
|
HCQ 200 mg NSAIDs |
HCQ 200 mg |
MTX 20 mg/w HCQ 150 mg |
||
|
Response to Tx |
NA |
good |
good |
good |
|
Other autoantibodies |
Ro, Su, U1RNP (Sm) |
Mi-2, Su |
||
|
ELISA (RP) TIF1α |
- |
- |
+ |
- |
|
TIF1β |
+ |
+ |
- |
- |
|
TIF1γ |
- |
- |
- |
- |
|
antigen-capture ELISA |
||||
|
TIF1α |
- |
- |
- |
- |
|
TIF1β |
+ |
+ |
weak + |
weak + |
|
|
||||
|
DM, dermatomyositis; ELISA, enzyme-linked immunosorbent assay; EMG, electromyogram; G, Gottron; H, heliotrope; HCQ, hydroxychloroquine; MTX, methotrexate; N, no; NA, not available; ND, not done; NSAIDs, non-steroid anti-inflammatory drugs; P, possible; PSL, prednisolone; RP, recombinant protein; S, shawl sign; TIF, transcription intermediary factor; Tx, treatment; UCTD, undifferentiated connective tissue disease; Y, yes; |
||||
|
Satoh et al. Arthritis Research & Therapy 2012 14:R79 doi:10.1186/ar3802 |
||||
